DONSON Antibody (N-term)
- Known as:
- DONSON Antibody (N-terminus)
- Catalog number:
- AP6567a
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- DONSON Antibody (N-term)
Related genes to: DONSON Antibody (N-term)
- Gene:
- DONSON NIH gene
- Name:
- downstream neighbor of SON
- Previous symbol:
- C21orf60
- Synonyms:
- B17, C2TA, DKFZP434M035
- Chromosome:
- 21q22.11
- Locus Type:
- gene with protein product
- Date approved:
- 2000-02-18
- Date modifiied:
- 2017-03-30
Related products to: DONSON Antibody (N-term)
Related articles to: DONSON Antibody (N-term)
- Diffuse midline gliomas (DMGs) are near-universally lethal tumours of the childhood central nervous system. In animal models, DMGs form brain-wide integrated networks through neuron-to-glioma synapses and glioma-to-glioma gap junctional coupling. This extensive connectivity robustly promotes the growth and invasion of DMG and other glial malignancies through paracrine mechanisms and direct neuron-to-glioma synapses. However, the organization and clinical implications of these connections in the living human brain remain to be elucidated. Here, we develop tumour network mapping to compute the brain-wide connectivity profile of DMG, defining a conserved brain network across pontine and thalamic DMG associated with patient short-term survival (DMG network). Tumour functional connectivity with the DMG network was independently predictive of patient overall survival across two external validation cohorts. Tumour growth mapped to DMG network-specific trajectories and peak in-network neurometabolic changes across development spatiotemporally aligned with the peak age incidence of DMG. Analyses of single-nucleus RNA sequencing data confirmed diverse synaptic gene enrichment in high-connectivity DMG. Strikingly, incidental surgical resection of high-connectivity thalamic DMG tissue conferred a significant survival advantage. Collectively, these data define a conserved and prognostically important brain network in children with DMG, consistent with the hypothesis that DMGs exploit otherwise healthy brain circuits to promote tumour growth. - Source: PubMed
Publication date: 2026/06/10
Sidpra JaiLind ValentinaCohen Alexander LSchaper Frederic L W V JStone Thomas JGrabovska YuraBiswas AsthikSudhakar SniyaSepulveda FranciscoPeres Bruno SVeronese GretaAlemán-Charlet CristinaOgunbiyi OlumideShamardani KiarashZhao JiaqiPalacin Alberto CastroMiller GillianOpipari Raffaella SDe Vita EnricoRidout DeborahFerraciolli Suely FLucato Leandro TAvsenik JernejPiccirilli EleonoraMorales-La Madrid AndrésMuchart JordiRyan Maura EPatel RajanHaldipur ParthivHill Ciaran SKrüger Marie TZrinzo LudvicJeelani Noor Ul OwaseMartinez-Barbera Juan PedroDonson Andrew MDorris KathleenMorgan Paul SMackay AlanVenkatesh Humsa SHorn AndreasMueller SabineGreen Adam LMirsky David MAkram HarithJones ChrisAquilina KristianMankad KshitijMonje MichelleJacques Thomas SFox Michael DHargrave Darren R - Ependymoma (EPN) is an aggressive pediatric central nervous system tumor with poor survival and significant morbidity. As immune factors are associated with outcome, the potential for effective immunotherapy in posterior fossa (PF) EPN has been suggested. Based on the success of immune stimulants combined with an anti-GD2 monoclonal antibody in high-risk pediatric neuroblastoma, we hypothesized that a similar approach would be a plausible immunotherapy strategy for recurrent PF EPN. - Source: PubMed
Griesinger Andrea MWidener MelissaDonson Andrew MMettetal AshleyHankinson Todd CHandler MichaelMulcahy Levy Jean MLindsay Holly BMacy Margaret EForeman Nicholas KDorris Kathleen - ZFTA-RELA is the most recurrent genetic alteration seen in paediatric supratentorial ependymoma (EPN) and is sufficient to initiate tumours in mice. Despite its oncogenic potential, ZFTA-RELA (ZR) is observed nearly exclusively in childhood EPN, with tumours located distinctly in the supratentorial brain of the central nervous system. We proposed that specific chromatin modules accessible during brain development would render distinct cell lineage programs at direct risk of transformation by ZR. To test this hypothesis, we performed combined single-nucleus assay for transposase-accessible chromatin and RNA (snMultiome) sequencing of the developing mouse forebrain compared with ZR-driven mouse and human EPN. We demonstrated that specific developmental lineage programs present in transient progenitor cells and regulated by PLAG/L family transcription factors were at risk of neoplastic transformation. Binding of this chromatin network by ZR or other PLAG/L family motifs targeting fusion oncoproteins led to persistent chromatin accessibility at oncogenic loci and oncogene expression. Cross-species analysis of mouse and human ZR EPN revealed significant cell type heterogeneity indicating incomplete neurogenic and gliogenic differentiation, with a small percentage of cycling progenitor-like or radial glial-like cells that established a putative tumour cell hierarchy. In vivo lineage tracing studies identified neoplastic clones that aggressively dominated tumour growth and established the entire EPN cellular hierarchy. These findings identify developmental epigenomic states that are critical for fusion-oncoprotein-driven transformation and show how these states continue to shape tumour progression. - Source: PubMed
Publication date: 2026/03/25
Kardian Alisha SSun HuaIppagunta SiriLaboe NicholasVaradharajan SrinidhiYu KwanhaChen Hsiao-ChiEmanus ErikZheng TuyuDeneen Riley MConnelly Jon PWang Yong-DongZhan JiangshanLiu HengxiLowe KimberleyBugbee TaylorPathak RakeshBland AmandaMehta SanyaCochiolo SophieArabzade AmirHolcomb BlakeBudd Kaitlin MKembuan GabrieleWright TristenCaesar EmmaPark MaxwellHancock AmeliaGee DavidMurdoch JoelXiao YiMcBrayer Samuel KMerchant Thomas EQi JunDurbin Adam DSchwarz Lindsay AWang LiDonson Andrew MForeman Nicholas KAgnihotri SameerLavado AlfonsoBaker Suzanne JEllison David WLee Hyun KyoungPruett-Miller Shondra MBertrand Kelsey CDeneen BenjaminMack Stephen C - A substantial body of literature exists on the perioperative management of pharmacological agents specifically prothrombotic agents, antiplatelets, anticoagulants and disease-modifying antirheumatic drugs (DMARDs) aimed at mitigating risks associated with both the medications themselves and the comorbidities they treat. However, a clear and consistent consensus on best practice is either lacking or poorly defined especially in foot surgery. To address this gap, a working group of podiatric surgeons convened to develop a Clinical Consensus Statement (CCS) for the perioperative management of these drugs in foot and ankle surgery. - Source: PubMed
Tang JadePosmyk LesleyCowden JamesLang RichardMilnes HelenDonson Lorna - Meier-Gorlin syndrome (MGORS) is a rare primordial dwarfism characterized by microtia, patellar hypoplasia/aplasia, and short stature. Additional features may include skeletal, respiratory, urogenital, and endocrine abnormalities. 13 genes have been implicated, with , essential for replication fork stability and intra-S phase checkpoint activation, being the most recently identified. Only six patients with -related MGORS have been reported. This study expands the phenotype by presenting long-term follow-up and prenatal data in two affected siblings. - Source: PubMed
Publication date: 2026/02/02
Sezer AbdullahYalçın Fatma ZehraKolkıran AbdulkerimÇetinkaya Semra